Plasma neurodegeneration biomarkers and clinical progression in early sporadic Parkinson's disease
Year: 2026
Type: preprint
Abstract: Objectives: Plasma neurodegeneration biomarkers offer an opportunity to characterize Parkinson's disease (PD) biology. The objective of this study was to investigate such biomarkers in deeply-phenotyped participants in Parkinson's Precision Medicine Initiative (PPMI). Methods: Baseline plasma samples from early (<2 years since diagnosis) sporadic PD participants with a positive CSF alpha-synuclein seed amplification assay (aSyn-SAA) and healthy controls (HC) with a negative aSyn-SAA test were utilized. Plasma P-tau217 (Roche Diagnostics), neurofilament light chain (NfL, Quanterix), glial fibrillary acidic protein (GFAP, Quanterix), and (PD only) amyloid-beta (Aβ) levels (40 and 42, C2N Diagnostics) were measured. Clinical features at baseline and over up to 11 years were compared across biomarker tertiles in models controlling for age, sex, and baseline outcome variable. Results: The cohort was 97 HC and 523 PD and participants. Median [IQR] biomarker values (pg/mL) for HC and PD were P-tau217: 0.14 [0.06 -0.75], 0.15 [0.06 -0.90]; NfL: 10.6 [3.13 -49.85], 12.26 [3.77-62.67]; GFAP: 66.56 [19.75 -403.48], 87.19 [14.55 -531.82]; and in PD Aβ40: 391.32 [209.95 -538.38]; Aβ42: 42.74[27.75 -68.55]. No biomarkers differed between HC and PD. In PD, biomarkers were associated with age. In PD only, higher baseline levels of P-tau217 and NfL were associated with greater hazards of a worse cognitive and balance outcome. P-tau217, NfL, and GFAP levels were associated with change in cognitive score over time. Interpretation: Plasma P-tau217, NfL and GFAP levels in early, sporadic PD with confirmed synucleinopathy predict future cognitive and functional impairment, and these findings can inform clinical research design and clinical care.
Source: medRxiv
Authors: Thomas F Tropea, David G Coughlin, Sarah M. Brooker, Krittika Chatterjee, Noah S. Johnson, Micah Marshall, Anuprita Nair, Javier E. Flores, David-Erick Lafontant, Christopher S Coffey, Kristopher M. Kirmess, Tim West, Philip B. Verghese, Kristen A. Russ, Amanda Morris, Ming Lu, Leonardo Iaccarino, Patricia Aldea-Stevenson, Matthew Flitter, Rose Beck, Samantha Hutten, Lana M. Chahine, Daniel Weintraub, Tatiana Foroud, Tanya Simuni, Kenneth Marek, Kalpana Merchant, The Parkinson's Precision Medicine Initiative
Institutions: Institute for Neurodegenerative Disorders, University of California San Diego, Northwestern University, University of Iowa, C2N Diagnostics (United States), Indiana University Indianapolis, Eli Lilly (United States), Michael J. Fox Foundation, University of California, San Francisco, University of California System, University of Pennsylvania, Indiana University School of Medicine
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: Parkinson's disease, plasma biomarkers, neurodegeneration, phosphorylated tau217, neurofilament light chain, glial fibrillary acidic protein, amyloid-beta, alpha-synuclein seed amplification assay, synucleinopathies, cognitive decline, balance disorders, clinical progression, early diagnosis
Open Access status: green
OpenAlex ID: W7237260959
